[go: up one dir, main page]

WO2007032029A1 - Peptides agonistes du facteur de croissance basique des fibroblastes (bfgf), et procede de reduction des rides, de repigmentation des cheveux et d'acceleration de la cicatrisation - Google Patents

Peptides agonistes du facteur de croissance basique des fibroblastes (bfgf), et procede de reduction des rides, de repigmentation des cheveux et d'acceleration de la cicatrisation Download PDF

Info

Publication number
WO2007032029A1
WO2007032029A1 PCT/IN2006/000370 IN2006000370W WO2007032029A1 WO 2007032029 A1 WO2007032029 A1 WO 2007032029A1 IN 2006000370 W IN2006000370 W IN 2006000370W WO 2007032029 A1 WO2007032029 A1 WO 2007032029A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitiligo
skin
treatment
bfgf
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2006/000370
Other languages
English (en)
Inventor
Abburi Ramaiah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/066,786 priority Critical patent/US20090069233A1/en
Priority to AU2006290251A priority patent/AU2006290251B2/en
Priority to EP06796204A priority patent/EP1942923A4/fr
Publication of WO2007032029A1 publication Critical patent/WO2007032029A1/fr
Anticipated expiration legal-status Critical
Priority to US12/764,530 priority patent/US8314065B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
    • A61Q5/065—Preparations for temporary colouring the hair, e.g. direct dyes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]

Definitions

  • This invention relates to agonist peptides of basic fibroblast growth factor (bFGF) and the method of reduction of wrinkles on skin, darkening of hair and acceleration of wound healing.
  • bFGF basic fibroblast growth factor
  • Basic fibroblast growth factor also known as FGF2 no named because it contains a high number of basic amino acid residues (Lysin, Arginie and histidine) is a potent mitogen for a variety of cell types including melanocytes, keratinocytes the major cell type in the epidermal unit and fibroblasts located in the dermis of skin. Both bovine and human bFGF were isolated and the genes expressing this product were sequenced and cloned. In addition bFGF was found to be expressed in a wide variety of tissue types including placenta, keratinocytes, fibroblasts.
  • bFGF may be involved in repigmentation of vitiligo macules a pigmentary disorder characterized by patchy depigmentation of skin (Ramaiah A, Puri, N, and Majamdar.M A new hypothesis for etiology of vitiligo in Acta Derma Venereol (Stochhom), 1989, 69,323-327). This idea was tested first on the vitro melanocyte cell cultures from the uninvolved areas of untreated vitiligo subjects and later on mixed cell cultures of melanocytes and keratinoytes obtained from the uninvolved areas of untreated vitiligo subjects. The
  • Patents of interest describing bFGF or peptides described above and the formulation for their penetration through intact skin include US Patent 0 no. 6,143723, AU Patent 722626, Indian Patents, 185613, 186437,
  • the peptides were tested on human volunteers suffering from vitiligo in the various phase of clinical trials in India and found to be successful in repigmenting about more than 80% volunteers with stable generalized 5 vitiligo and segmental vitiligo.
  • Skin is subject to aging and is visible to the naked eyes.
  • the aging process of skin can be divided into chrono aging and photo aging.
  • the former is a normal aging process and can be accelerated by the exposure of skin to sun, which is known as photo aging.
  • skin is subject to deterioration through the dermatological disorders, environmental abuse.
  • Collagen- 1 represents more than 70% (Uitto J. Connective tissue biochemistry of the aging dermis: Age related alterations in collagen and elastin: Dermatio. Clin (1986) 4:433-46) of the dermis of the skin. Dermal collagen content peaks in the third decade of life and declines gradually at a rate approximately 1% per year thereafter in men and women (Artho P. Skin thickness and collagen content in some endocrine, connective tissue and skin diseases. Acta derm. Veneroeol Suppl (Stockh) 1972: 69: 1-48.
  • Meema HE Sheppard RH, Roentgeno graphic visualization and measurement of skin thickness and its diagnostic application to acromegaly, Radiology (1964); 82:411-7, Shuster S, BlackMM, Mc Vitie E:. The influence of age and sex on skin thickness, skin collagen and density Br J Dermatol (1975); 93:639-43, Shuster S Bottoms E senile feneration of skin collagen in men. In women it may be so after the fifth decade of life.
  • Collagen is the predominant matrix skin protein and is known to impart tensile strength to skin.
  • Decorin is proteoglycan, which is known to be important for controlled and correct deposition of collagen in the extracellular matrix of skin. It is also known in the art that the levels of collagen and decorin in skin are significantly reduced with age and/ or photo damaged skin. Many studies had shown that the levels of collagen type 1 in skin are decreased with age and/ or with increased photo damage (Lavaker R, Jour. Invest. Dermatol (1979); 73:59-66 Griffiths et al New. Eng J. med (1993); 329, 530-535).
  • Wrinkles on the face are due to repeated nerve stimulation that result in repeated facial muscle contractions, in addition to reduction in the amount of collagen, elastin and subcutaneous fat in the skin.
  • AU atjti wrinkling agents which reduce the nerve stimulation and thus facial muscle contractions can help in the reduction of fine lines and wrinkles on the face.
  • Wrinkle reduction on the rest of the skin on the body including the skin on the face should essentially be by increasing the synthetic of collagen, retention in the skin of moisture.
  • retionic acid is potent anti-aging agent and indues dermal repair of photo damaged skin. It was shown that wrinkle effacement and dermal repair following topical treatment of skin with retionic acid arises through new collagen deposition and synthetic in skin (Griffiths et al New, Eng. J, Med (1993); 329, 530-535).
  • Ah object of the present invention is to propose a peptide and composition containing said peptide for reducing the formation of wrinkles on skin.
  • Another object of this invention is to propose a peptide and a composition containing said peptide, for darkening of hair.
  • the peptides consisting of sequence 1-8 listed herein for darkening and reduce formation of wrinkles on skin.
  • the peptides are present in the range of 0.02-5% w/w in the composition are effective when applied topically in the formulation for reduction of wrinkles on skin, in acceleration of wound healing and in darkening of hair. They can be applied in the form of lotion, gels, creams or in the case of wound healing in the form of sterile phosphate buffer isotonic saline or in glycerine if applied to cure muscositis in oral cavity.
  • the mode of administration is not restricted to the above methods.
  • these peptides increase the proliferation of melanocytes located not only in the dermal epidermal junction but also the melaonocytes located in the hair follicles, as indicated in the taken before and after the topical application of these peptides for 3-6 months.
  • Peptides derived from bFGF accelerate wound healing
  • a method of accelerating wound healing on skin by topical application of an effective amount of a composition in sterile phosphate buffered isotonic saline solution that comprises 0.02-5% w/w of at least one peptide selected from a group consisting for SEQ ID NO 1-8 reference may be made to US Patent no.
  • sequence listing is given as follows :- (2) Information for Sequence ID NO: 1
  • Sequence Description Sequence ID NO: 2: an invention Tyr Arg Ser Arg Lys Tyr GIu Ser Trp Tyr amide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention se rapporte à des thérapies synergiques destinées à traiter le vitiligo, trouble de la pigmentation caractérisé par une dépigmentation de la peau sous forme de taches. Les principales thérapies destinées à traiter le vitiligo sont la puvathérapie, association de psoralènes et d'UVA, l'administration de stéroïdes, la localisation du ou des peptides du facteur de croissance basique des fibroblastes (bFGF), ou la chirurgie. La puvathérapie est efficace dans environ 50 % des cas. Les stéroïdes ont une efficacité limitée, et sont utiles uniquement pour les cas de vitiligo à évolution rapide, la maladie réapparaissant à l'arrêt du traitement. Le traitement chirurgical n'est employé pour la thérapie du vitiligo qu'en dernier recours, lorsque toutes les autres thérapies ont échoué, et a une efficacité limitée. La localisation du ou des peptides du facteur de croissance basique des fibroblastes, mise au point récemment, est un nouveau mode de traitement du vitiligo. Elle est efficace dans 80 % des cas de vitiligo stable et segmentaire. L'invention fournit des données démontrant que le traitement combinatoire du vitiligo par l'application locale d'une lotion de peptides bFGF associée à la puvathérapie, à des stéroïdes ou à un acte chirurgical, produit une réponse synergique, le taux de repigmentation augmentant de manière synergique, et les résultats obtenus étant plus efficaces qu'avec une seule desdites techniques. La thérapie combinatoire consistant en l'application locale d'une lotion de peptides bFGF sur la tache de vitiligo combinée à l'administration de tout autre mode de traitement du vitiligo semble produire un effet synergique.
PCT/IN2006/000370 2005-09-13 2006-09-11 Peptides agonistes du facteur de croissance basique des fibroblastes (bfgf), et procede de reduction des rides, de repigmentation des cheveux et d'acceleration de la cicatrisation Ceased WO2007032029A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/066,786 US20090069233A1 (en) 2005-09-13 2006-09-11 Agonist Peptides of Basic Fibroblast Growth Factor (bFGF) and the Method of Reduction of Wrinkles on Skin, Darkening of Hair and Acceleration of Wound Healing
AU2006290251A AU2006290251B2 (en) 2005-09-13 2006-09-11 Agonist peptides of basic fibroblast growth factor (BFGF) and the method of reduction of wrinkle on skin, darkening of hair and acceleration of wound healing
EP06796204A EP1942923A4 (fr) 2005-09-13 2006-09-11 Peptides agonistes du facteur de croissance basique des fibroblastes (bfgf), et procede de reduction des rides, de repigmentation des cheveux et d'acceleration de la cicatrisation
US12/764,530 US8314065B2 (en) 2005-09-13 2010-04-21 Method of reduction of wrinkles on skin or acceleration of wound healing by applying peptides related to basic fibroblast growth factor (bFGF)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN847KO2005 2005-09-13
IN847/KOL/2005 2005-09-13

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/066,786 A-371-Of-International US20090069233A1 (en) 2005-09-13 2006-09-11 Agonist Peptides of Basic Fibroblast Growth Factor (bFGF) and the Method of Reduction of Wrinkles on Skin, Darkening of Hair and Acceleration of Wound Healing
US12/764,530 Division US8314065B2 (en) 2005-09-13 2010-04-21 Method of reduction of wrinkles on skin or acceleration of wound healing by applying peptides related to basic fibroblast growth factor (bFGF)

Publications (1)

Publication Number Publication Date
WO2007032029A1 true WO2007032029A1 (fr) 2007-03-22

Family

ID=37864650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000370 Ceased WO2007032029A1 (fr) 2005-09-13 2006-09-11 Peptides agonistes du facteur de croissance basique des fibroblastes (bfgf), et procede de reduction des rides, de repigmentation des cheveux et d'acceleration de la cicatrisation

Country Status (4)

Country Link
US (2) US20090069233A1 (fr)
EP (2) EP2489363A3 (fr)
AU (1) AU2006290251B2 (fr)
WO (1) WO2007032029A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009235004A (ja) * 2008-03-27 2009-10-15 J Hewitt Kk 細胞組織増加促進方法及び肌問題改善方法並びにこれらに用いるキット
WO2009039980A3 (fr) * 2007-09-11 2009-11-26 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
EP2263683A4 (fr) * 2008-03-28 2013-11-13 Labo Juversa Co Ltd Agent pour traiter le vieillissement de la peau et les cicatrices
US20150152139A1 (en) * 2013-11-29 2015-06-04 Escape Therapeutics, Inc. Peptide Tyrosinase Activators
WO2017087034A1 (fr) * 2015-11-19 2017-05-26 Avon Products, Inc. Peptides et leur utilisation dans le traitement de la peau
WO2018183882A1 (fr) * 2017-03-30 2018-10-04 Escape Therapeutics, Inc. Modulation par le décapeptide 12 de l'expression du gène de sirtuine dans des progéniteurs de kératinocytes épidermiques
WO2019142124A1 (fr) * 2018-01-17 2019-07-25 Cadila Healthcare Limited Compositions pharmaceutiques pour le traitement du vitiligo
FR3077202A1 (fr) * 2018-02-01 2019-08-02 Sederma Utilisation de cyclopeptides en cosmetique
WO2020152568A1 (fr) * 2019-01-21 2020-07-30 Globetech Innovation S.R.O. Mélange de constituants peptidiques pour le renouvellement et la cicatrisation de la peau et son utilisation
RU2781194C2 (ru) * 2017-03-30 2022-10-07 Эскейп Терапьютикс, Инк. Модуляция гена сиртуина в предшественниках эпидермальных кератиноцитов с помощью декапептида-12
WO2023131829A1 (fr) 2022-01-05 2023-07-13 Ramakrishna Reddy Isanaka Formulation pour le traitement de troubles pigmentaires

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013165252A1 (fr) 2012-05-03 2013-11-07 Erasmus University Medical Center Rotterdam Culture de cellules souches mésenchymateuses
KR20210116493A (ko) * 2019-01-19 2021-09-27 이스케이프 테라퓨틱스, 인코퍼레이티드 인간 신생아 각질형성세포 전구체에서 면역억제 활성을 갖는 티로신 억제제
CN115884752A (zh) 2020-06-26 2023-03-31 米尼翁大学 用于毛囊调节的组合物、方法及其用途
WO2022182737A2 (fr) * 2021-02-23 2022-09-01 Northwestern University Échafaudages bioactifs dynamiques et leurs utilisations thérapeutiques après une lésion du snc
WO2023119230A1 (fr) 2021-12-22 2023-06-29 L'oreal Compositions de modulation de la voie de coagulation et de la voie de nicotinamide-adénine dinucléotide et leurs procédés d'utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0543442A (ja) * 1991-08-14 1993-02-23 Sansho Seiyaku Co Ltd 皮膚化粧料
US6143723A (en) * 1996-05-20 2000-11-07 Ramaiah; Abburi Pigmentory agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252718A (en) * 1986-04-22 1993-10-12 The Salk Institute For Biological Studies Fibroblast growth factor antagonists
DE3750197D1 (de) * 1986-04-22 1994-08-18 Salk Inst For Biological Studi Antagonisten des Fibroblasten-Wachstumsfaktors.
US5013714A (en) * 1988-12-15 1991-05-07 Lindstrom Richard L Viscoelastic solution
US5492894A (en) * 1991-03-21 1996-02-20 The Procter & Gamble Company Compositions for treating wrinkles comprising a peptide
DE69205466T2 (de) * 1991-03-21 1996-05-30 Procter & Gamble Mittel zur Kontrolle von Hautfalten, die die Arg-Ser-Arg-Lys-Sequenzen enthalten.
AU722626B2 (en) * 1996-05-20 2000-08-10 Abburi Ramaiah Cosmetic preparation
IN185703B (fr) 1996-05-20 2001-04-14 Ramaiah Abburi
IN186437B (fr) 1997-03-07 2001-09-01 Abburi Ramaiah

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0543442A (ja) * 1991-08-14 1993-02-23 Sansho Seiyaku Co Ltd 皮膚化粧料
US6143723A (en) * 1996-05-20 2000-11-07 Ramaiah; Abburi Pigmentory agent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199313, Derwent World Patents Index; AN 1993-104177, XP003010233 *
See also references of EP1942923A4 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009039980A3 (fr) * 2007-09-11 2009-11-26 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
JP2009235004A (ja) * 2008-03-27 2009-10-15 J Hewitt Kk 細胞組織増加促進方法及び肌問題改善方法並びにこれらに用いるキット
EP2263683A4 (fr) * 2008-03-28 2013-11-13 Labo Juversa Co Ltd Agent pour traiter le vieillissement de la peau et les cicatrices
US9023792B2 (en) 2008-03-28 2015-05-05 Labo Juversa Co., Ltd. Method for treating keloid and hypertrophic scars by administration of bFGF
US20150152139A1 (en) * 2013-11-29 2015-06-04 Escape Therapeutics, Inc. Peptide Tyrosinase Activators
US9567368B2 (en) * 2013-11-29 2017-02-14 Escape Therapeutics, Inc. Peptide tyrosinase activators
WO2017087034A1 (fr) * 2015-11-19 2017-05-26 Avon Products, Inc. Peptides et leur utilisation dans le traitement de la peau
RU2781194C2 (ru) * 2017-03-30 2022-10-07 Эскейп Терапьютикс, Инк. Модуляция гена сиртуина в предшественниках эпидермальных кератиноцитов с помощью декапептида-12
CN110770248A (zh) * 2017-03-30 2020-02-07 伊斯卡皮医疗公司 表皮角质形成细胞祖细胞中去乙酰化酶基因表达的十肽-12调控
JP2020513031A (ja) * 2017-03-30 2020-04-30 エスケープ・セラピューティクス・インコーポレイテッドＥｓｃａｐｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 表皮ケラチノサイト前駆細胞におけるサーチュイン遺伝子発現のデカペプチド−１２モジュレーション
WO2018183882A1 (fr) * 2017-03-30 2018-10-04 Escape Therapeutics, Inc. Modulation par le décapeptide 12 de l'expression du gène de sirtuine dans des progéniteurs de kératinocytes épidermiques
JP7620429B2 (ja) 2017-03-30 2025-01-23 エスケープ・セラピューティクス・インコーポレイテッド 表皮ケラチノサイト前駆細胞におけるサーチュイン遺伝子発現のデカペプチド－１２モジュレーション
WO2019142124A1 (fr) * 2018-01-17 2019-07-25 Cadila Healthcare Limited Compositions pharmaceutiques pour le traitement du vitiligo
FR3077202A1 (fr) * 2018-02-01 2019-08-02 Sederma Utilisation de cyclopeptides en cosmetique
WO2019149450A1 (fr) * 2018-02-01 2019-08-08 Sederma Utilisation de peptides cycliques dans un produit cosmétique
CN111670027A (zh) * 2018-02-01 2020-09-15 赛德玛公司 环肽在美容中的用途
WO2020152568A1 (fr) * 2019-01-21 2020-07-30 Globetech Innovation S.R.O. Mélange de constituants peptidiques pour le renouvellement et la cicatrisation de la peau et son utilisation
IL284670B1 (en) * 2019-01-21 2024-07-01 Globetech Innovation S R O Skin renewing and healing mixture of peptide components and its use
IL284670B2 (en) * 2019-01-21 2024-11-01 Globetech Innovation S R O Skin renewing and healing mixture of peptide components and its use
WO2023131829A1 (fr) 2022-01-05 2023-07-13 Ramakrishna Reddy Isanaka Formulation pour le traitement de troubles pigmentaires

Also Published As

Publication number Publication date
EP1942923A1 (fr) 2008-07-16
EP1942923A4 (fr) 2010-01-06
AU2006290251B2 (en) 2011-12-08
US20100323962A1 (en) 2010-12-23
AU2006290251A2 (en) 2008-05-29
AU2006290251A1 (en) 2007-03-22
US8314065B2 (en) 2012-11-20
US20090069233A1 (en) 2009-03-12
EP2489363A3 (fr) 2012-12-05
EP2489363A2 (fr) 2012-08-22

Similar Documents

Publication Publication Date Title
US8314065B2 (en) Method of reduction of wrinkles on skin or acceleration of wound healing by applying peptides related to basic fibroblast growth factor (bFGF)
CA2063610C (fr) Methode pour le traitement du vieillissement de la peau ou de la peau endommagee par les rayons ultra-violets
EP0389470B1 (fr) Agent cosmetique et preparation servant au traitement de l'epiderme
US20120315259A1 (en) Method and composition for skin care comprising cord blood serum or plasma or components thereof
EP1074240B1 (fr) Réduction de la croissance capillaire, de la taille du follicule et du pore pileux et de la pigmentation capillaire
RU2602861C2 (ru) Синтез эластического волокна in vivo
WO2002005828A1 (fr) Compositions et procedes pour traiter des dommages cutanes
CN116546971A (zh) 组织源性基质因子组合物和其方法
US20230363999A1 (en) Composition for treating hair loss or promoting hair growth comprising growth factor
JP2022516961A (ja) 化粧料に使用するためのペプチドおよび組成物
US20020081324A1 (en) Method of treating aging skin and wrinkles using a combination of growth factors that is commercially prepared or derived from one's own blood
JP5306647B2 (ja) 少なくとも１種類の天然Ａｃ−Ｎ−Ｓｅｒ−Ａｓｐ−Ｌｙｓ−Ｐｒｏテトラペプチドまたはその類似体の１つの、皮膚老化防止および再構築剤としての美容的使用
US8778891B2 (en) Dermatopontin-activating peptides and cosmetic compositions including same
Klokol et al. Application of cell extracts from skin, placenta, mesenchyme with collagen and elastin in aesthetic dermatology and skin revitalization: evaluation of outcomes in cohort study
US20080193403A1 (en) Inducing And Maintaining Hair Color
WO2007002594A1 (fr) Compositions cosmetiques et procedes faisant appel a des mimetiques de transformation du facteur de croissance beta
CN115515622A (zh) 用于皮肤状况的衍生自乙酰胆碱酯酶c-末端的多肽
EA023680B1 (ru) Интерлейкин-1 бета в косметических композициях и способы его использования
KR20040056365A (ko) 재조합 인간 표피성장인자를 함유하는 화장료 조성물
US20070154421A1 (en) Method of treating skin needing collagen treatment
Khalid et al. Anti-Aging topical peptides and proteins
Fasola et al. Pilot study evaluating the therapeutic effects of a new pre-mixed injectable product of low molecular weight (LMW) hyaluronic acid added to six amino acids (HY6AA+ Formula) in facial skin aging
WO1994012534A2 (fr) Inhibiteur melanogene, et procedes de preparation et d'utilisation
KR20040076780A (ko) 재조합 인슐린 유사 성장인자를 함유하는 화장료 조성물
AU2002222911B2 (en) Compositions and methods for the treatment of skin damage

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006796204

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006290251

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006290251

Country of ref document: AU

Date of ref document: 20060911

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006290251

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006796204

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12066786

Country of ref document: US